Sangamo Therapeutics chopping 120 jobs after Biogen, Novartis exit deals

The company's non-partnered programs will zero in on Fabry Disease gene therapy, a cell therapy for certain kidney transplant recipients and preclinical therapies targeting prions diseases and neurology.

Source: bizjournals.com Health Care:Biotechnology headlines - May 1, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news